A large online registry targeting the assessment of Alzheimer’s disease utilized the Cogstate Brief Battery™. 75,491 participants completed independent, at-home tests every 3-6 months, resulting in extensive baseline (57,000) and longitudinal (28,000) data collection for the study team. Cogstate tests have high usability for the remote assessment of cognition. (Mackin et al. Alzheimers Dement 2018 Jun 21;10:573-582. Nosheny et al. Alzehimers Dement 2018 Oct 15;4:565-574. Weiner et al. Alzheimers Dement 2018 Aug;14(8):1063-1076)

The Vineland-3 is a widely used measure of adaptive functioning in rare disease clinical trials. In one program of clinical trials, 53 site raters administered the assessment; in another program of clinical trials, 7 central raters administered the assessment. An analysis of these results showed the use of central raters offered greater efficiency and optimized data quality by decreasing rater variance, while also reducing the burden on sites. (Ventola, et al, “Leveraging Remote Assessment and Central Raters to Optimize Data Quality in Rare Neurodevelopment Disorders Clinical Trials,” ECRD, 2022)

• The team of 7 central raters conducted 150 administrations (~21 per person) compared to the 53 site raters who conducted 138 administrations (~2.5 per person).  
• 0 of the administrations completed by the central raters had significant errors, compared to the site raters which had 4 administrations with errors that compromised the validity of the assessment.